CA2431881A1 - Polypeptide inducing hiv-neutralising antibodies - Google Patents
Polypeptide inducing hiv-neutralising antibodies Download PDFInfo
- Publication number
- CA2431881A1 CA2431881A1 CA002431881A CA2431881A CA2431881A1 CA 2431881 A1 CA2431881 A1 CA 2431881A1 CA 002431881 A CA002431881 A CA 002431881A CA 2431881 A CA2431881 A CA 2431881A CA 2431881 A1 CA2431881 A1 CA 2431881A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- conjugate
- group
- mutation selected
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract 13
- 229920001184 polypeptide Polymers 0.000 title claims abstract 12
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract 12
- 230000001939 inductive effect Effects 0.000 title claims 2
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims abstract 2
- 229960005486 vaccine Drugs 0.000 claims abstract 2
- 230000035772 mutation Effects 0.000 claims 4
- 102220554407 Choriogonadotropin subunit beta 3_T35I_mutation Human genes 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 102220603072 Transcription factor SOX-4_W37A_mutation Human genes 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 102220639932 40S ribosomal protein S17_D98A_mutation Human genes 0.000 claims 1
- 102220639930 40S ribosomal protein S17_R99A_mutation Human genes 0.000 claims 1
- 102220547923 ASNSD1 upstream open reading frame protein_G38A_mutation Human genes 0.000 claims 1
- 102220546945 ASNSD1 upstream open reading frame protein_Q39A_mutation Human genes 0.000 claims 1
- 102220485589 CHRNA7-FAM7A fusion protein_Q41A_mutation Human genes 0.000 claims 1
- 102000014914 Carrier Proteins Human genes 0.000 claims 1
- 108010078791 Carrier Proteins Proteins 0.000 claims 1
- 102220499761 Epiphycan_C70S_mutation Human genes 0.000 claims 1
- 102220592449 Non-homologous end-joining factor 1_Q43A_mutation Human genes 0.000 claims 1
- 102220625539 PSME3-interacting protein_Q18A_mutation Human genes 0.000 claims 1
- 102220550339 Protein unc-50 homolog_L47A_mutation Human genes 0.000 claims 1
- 102220582101 Putative uncharacterized protein FER1L6-AS1_Q17A_mutation Human genes 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 102220401810 c.110G>C Human genes 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 102220197780 rs121434596 Human genes 0.000 claims 1
- 102220264184 rs1554736515 Human genes 0.000 claims 1
- 102200100439 rs2304681 Human genes 0.000 claims 1
- 102220272831 rs55851803 Human genes 0.000 claims 1
- 102220059793 rs786202542 Human genes 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The invention concerns a polypeptide capable of forming a structure corresponding or analogous to the intermediate state of gp41 and its use in a vaccine for preventing and treating HIV-mediated infections.
Claims (11)
1. A polypeptide capable of forming a structure corresponding to or mimicking the intermediate state of gp41, comprising at least one mutation selected from the group consisting of: I101D or S.
2. The polypeptide as claimed in claim 1, of sequence SEQ ID No. 2 and comprising at least one mutation selected from the group consisting of:
I101D or S.
I101D or S.
3. The polypeptide as claimed in claim 1 or 2, comprising at least one other mutation selected from the group comprising: G13A, L, M, I, W or K;
Q17A or E; Q18A or E; A24Q, E, S or R; Q28A; T35I
or L; V36Q or E; W37S or D; G38A, V, L, I, M or E;
Q39A, V, L, I, M or E; K40E, A, V, L, I or M;
Q41A, V, L, I, M or E; Q43A, V, L, I, M or E; L47A
or D; V49I or L; R51A, N or E; Q56I; C64S; C70S;
or L; W94D; D98A, V, L, I, M or K; R99A, N or E;
Y104M or E; I108D; Q119A, V, L, I, M, S, N or R;
E120A; K121A; E123A; E125A; R153N or A and R173N
or A.
Q17A or E; Q18A or E; A24Q, E, S or R; Q28A; T35I
or L; V36Q or E; W37S or D; G38A, V, L, I, M or E;
Q39A, V, L, I, M or E; K40E, A, V, L, I or M;
Q41A, V, L, I, M or E; Q43A, V, L, I, M or E; L47A
or D; V49I or L; R51A, N or E; Q56I; C64S; C70S;
or L; W94D; D98A, V, L, I, M or K; R99A, N or E;
Y104M or E; I108D; Q119A, V, L, I, M, S, N or R;
E120A; K121A; E123A; E125A; R153N or A and R173N
or A.
4. The polypeptide as claimed in any one of claims 1 to 3, comprising the following mutations: T35I +
Q28I + I101D; T35I + Q28I + I101D + Q119N; I101D +
I108D + Q131N + W37A; I101D + I108D + Q142N +
L126D; W37A + I101D + I108D + Q119N; or I101D +
I108D + Q119N + L126D.
Q28I + I101D; T35I + Q28I + I101D + Q119N; I101D +
I108D + Q131N + W37A; I101D + I108D + Q142N +
L126D; W37A + I101D + I108D + Q119N; or I101D +
I108D + Q119N + L126D.
5. A conjugate comprising a polypeptide as claimed in one of claims 1 to 4, conjugated to a carrier protein or peptide.
6. A DNA sequence encoding a polypeptide as claimed in any one of claims 1 to 4 or encoding a conjugate as claimed in claim 5.
7. An expression vector comprising the DNA sequence as claimed in claim 6.
8. A host cell containing the vector as claimed in claim 7.
9. A process for preparing a polypeptide as claimed in any one of claims 1 to 5, comprising the expression of said polypeptide using a host cell as defined in claim 8.
10. A vaccine against HIV, comprising at least one polypeptide as claimed in one of claims 1 to 4, at least one conjugate as claimed in claim 5 or at least one expression vector as claimed in claim 7, a pharmaceutically acceptable support and, optionally, an adjuvant.
11. The use of a polypeptide as claimed in any one of claims 1 to 4, for preparing a medicinal product for inducing antibodies which neutralize primary isolates of HIV.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR01/00141 | 2001-01-05 | ||
| FR0100141A FR2819256B1 (en) | 2001-01-05 | 2001-01-05 | POLYPEPTIDE INDUCING HIV NEUTRALIZING ANTIBODIES |
| FR01/00848 | 2001-01-23 | ||
| FR0100848 | 2001-01-23 | ||
| PCT/FR2002/000031 WO2002053587A2 (en) | 2001-01-05 | 2002-01-04 | Polypeptide inducing hiv-neutralising antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2431881A1 true CA2431881A1 (en) | 2002-07-11 |
| CA2431881C CA2431881C (en) | 2011-02-22 |
Family
ID=26212817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2431881A Expired - Fee Related CA2431881C (en) | 2001-01-05 | 2002-01-04 | Polypeptide inducing hiv-neutralising antibodies |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1368478B1 (en) |
| AT (1) | ATE324450T1 (en) |
| AU (1) | AU2002229850A1 (en) |
| CA (1) | CA2431881C (en) |
| CY (1) | CY1105629T1 (en) |
| DE (1) | DE60210936T2 (en) |
| DK (1) | DK1368478T3 (en) |
| ES (1) | ES2260416T3 (en) |
| PT (1) | PT1368478E (en) |
| WO (1) | WO2002053587A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8372955B2 (en) | 2003-02-06 | 2013-02-12 | Assistance Publique Hopitaux De Paris | Purified antibody to the extracellular domain of NKp44L |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60336978D1 (en) | 2003-04-11 | 2011-06-16 | Pasteur Institut | Synthetic peptide HIV vaccine: the CBD epitope as an efficient immunogen for the induction of HIV-neutralizing antibodies |
| CA2558733C (en) * | 2004-02-06 | 2016-04-19 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | A polypeptide derived from gp41, a vaccine composition comprising said polypeptide, and uses for treating an infection by an hiv virus in an individual |
| WO2014020205A2 (en) * | 2012-07-31 | 2014-02-06 | Universidad De Granada | Improved anti-hiv immunogens |
| CN108997482A (en) * | 2018-08-09 | 2018-12-14 | 东莞市朋志生物科技有限公司 | for detecting the synthetic peptide of HIV-1 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000008043A2 (en) * | 1998-08-03 | 2000-02-17 | The University Of Montana | Prevention and treatment of viral disease |
| JP2003529319A (en) * | 1999-01-08 | 2003-10-07 | キャロル ディ． ウエイス， | Methods of eliciting broadly neutralizing antibodies targeting HIV-1 gp41 |
-
2002
- 2002-01-04 EP EP02710945A patent/EP1368478B1/en not_active Expired - Lifetime
- 2002-01-04 ES ES02710945T patent/ES2260416T3/en not_active Expired - Lifetime
- 2002-01-04 AU AU2002229850A patent/AU2002229850A1/en not_active Abandoned
- 2002-01-04 DE DE60210936T patent/DE60210936T2/en not_active Expired - Lifetime
- 2002-01-04 PT PT02710945T patent/PT1368478E/en unknown
- 2002-01-04 CA CA2431881A patent/CA2431881C/en not_active Expired - Fee Related
- 2002-01-04 WO PCT/FR2002/000031 patent/WO2002053587A2/en active IP Right Grant
- 2002-01-04 AT AT02710945T patent/ATE324450T1/en active
- 2002-01-04 DK DK02710945T patent/DK1368478T3/en active
-
2006
- 2006-06-28 CY CY20061100881T patent/CY1105629T1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8372955B2 (en) | 2003-02-06 | 2013-02-12 | Assistance Publique Hopitaux De Paris | Purified antibody to the extracellular domain of NKp44L |
Also Published As
| Publication number | Publication date |
|---|---|
| ATE324450T1 (en) | 2006-05-15 |
| CY1105629T1 (en) | 2010-12-22 |
| WO2002053587A3 (en) | 2003-09-25 |
| AU2002229850A1 (en) | 2002-07-16 |
| EP1368478A2 (en) | 2003-12-10 |
| ES2260416T3 (en) | 2006-11-01 |
| CA2431881C (en) | 2011-02-22 |
| DE60210936T2 (en) | 2006-10-19 |
| DK1368478T3 (en) | 2006-08-28 |
| DE60210936D1 (en) | 2006-06-01 |
| PT1368478E (en) | 2006-07-31 |
| WO2002053587A2 (en) | 2002-07-11 |
| EP1368478B1 (en) | 2006-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5444044A (en) | Synthetic polypeptides as inhibitors of HIV-1 | |
| CA2330235A1 (en) | Antigenic complex comprising immunostimulatory peptide, cd4, and chemokine receptor domain for hiv treatment and immune disorders | |
| CA2164818A1 (en) | Tandem synthetic hiv-1 peptides | |
| MY136081A (en) | Modified hiv - 1gag p17 peptide and immunogenic composition | |
| CA2363947A1 (en) | Hiv peptides, antigens, vaccine compositions, immunoassay kit and a method of detecting antibodies induced by hiv | |
| CA2082948A1 (en) | Immunogenic peptides, antibodies and uses thereof relating to cd4 receptor binding | |
| EP2311958A3 (en) | Polynucleotides encoding antigenic HIV type C polypeptides, polypeptides and uses thereof | |
| GR3031790T3 (en) | Composite synthetic peptide construct eliciting neutralizing antibodies and cytotoxic t lymphocytes against hiv | |
| EP1461079B8 (en) | Human immunodeficiency virus envelope glycoprotein mutants and uses thereof | |
| GB9911683D0 (en) | Antigenic peptides | |
| US7105655B2 (en) | Stabilization of envelope glycoprotein trimers by disulfide bonds introduced into a gp41 glycoprotein ectodomain | |
| CA2248667A1 (en) | Hla-a2.1 binding peptides and their uses | |
| CA2380833A1 (en) | Proteins derived from white spot syndrome virus and uses thereof | |
| AU4826493A (en) | Anti-feline immunodeficiency virus (fiv) vaccines | |
| CA2431881A1 (en) | Polypeptide inducing hiv-neutralising antibodies | |
| EP1019511A2 (en) | STABILIZATION OF ENVELOPE GLYCOPROTEIN TRIMERS BY DISULFIDE BONDS INTRODUCED INTO A gp41 GLYCOPROTEIN ECTODOMAIN | |
| PT1417222E (en) | Isolated polypeptides based on the neutralizing epitope of the p17 protein of hiv useful as vaccines, and neutralizing anti-p17 antibodies which specifically recognize said neutralizing epitope | |
| AU5776799A (en) | Modified hcv peptide vaccines | |
| CA2254082A1 (en) | Metastatic colorectal cancer vaccine | |
| CA2128407A1 (en) | Synthetic peptides for a rubella vaccine | |
| US6379679B1 (en) | Multiple branch peptide construction | |
| WO2002069691A3 (en) | Immunogenic hiv peptides for use as reagents and vaccines | |
| WO2003029285A3 (en) | Identification of cd8 epitopes from hiv-1 proteins for prevention and therapy of hiv infections | |
| CA2223503A1 (en) | Transferrin receptor genes | |
| NZ508812A (en) | Peptides for the prevention or treatment of HIV |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20150105 |